Ability of NAD and Sirt1 to epigenetically suppress albuminuria-Reference-Cited by-同舟云学术

Ability of NAD and Sirt1 to epigenetically suppress albuminuria

Published:2024-04-08 Issue:7 Volume:28 Page:599-607
ISSN:1342-1751
Container-title:Clinical and Experimental Nephrology
language:en
Short-container-title:Clin Exp Nephrol

Author:

Hasegawa Kazuhiro^ORCID,Tamaki Masanori,Shibata Eriko,Inagaki Taizo,Minato Masanori,Yamaguchi Sumiyo,Shimizu Ikuko,Miyakami Shinji,Tada Miho,Wakino Shu

Abstract

AbstractThe time for diabetic nephropathy (DN) to progress from mild to severe is long. Thus, methods to continuously repress DN are required to exert long-lasting effects mediated through epigenetic regulation. In this study, we demonstrated the ability of nicotinamide adenine dinucleotide (NAD) and its metabolites to reduce albuminuria through Sirt1- or Nampt-dependent epigenetic regulation. We previously reported that proximal tubular Sirt1 was lowered before glomerular Sirt1. Repressed glomerular Sirt1 was found to epigenetically elevate Claudin-1. In addition, we reported that proximal tubular Nampt deficiency epigenetically augmented TIMP-1 levels in Sirt6-mediated pathways, leading to type-IV collagen deposition and diabetic fibrosis. Altogether, we propose that the Sirt1/Claudin-1 axis may be crucial in the onset of albuminuria at the early stages of DN and that the Nampt/Sirt6/TIMP-1 axis promotes diabetic fibrosis in the middle to late stages of DN. Finally, administration of NMN, an NAD precursor, epigenetically potentiates the regression of the onset of DN to maintain Sirt1 and repress Claudin-1 in podocytes, suggesting the potential use of NAD metabolites as epigenetic medications for DN.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10157-024-02502-w.pdf

Reference34 articles.

1. Hasegawa K, Wakino S, Simic P, Sakamaki Y, Minakuchi H, Fujimura K, Hosoya K, Komatsu M, Kaneko Y, Kanda T, Kubota E, Tokuyama H, Hayashi K, Guarente L, Itoh H. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med. 2013;19(11):1496–504. https://doi.org/10.1038/nm.3363.

2. Hasegawa K, Wakino S, Sakamaki Y, Muraoka H, Umino H, Minakuchi H, Yoshifuji A, Naitoh M, Shinozuka K, Futatsugi K, Urai H, Kanda T, Tokuyama H, Hayashi K, Itoh H. Communication from tubular epithelial cells to podocytes through Sirt1 and nicotinic acid metabolism. Curr Hypertens Rev. 2016;12(2):95–104. https://doi.org/10.2174/1573402112666160302102217.

3. Yasuda I, Hasegawa K, Sakamaki Y, Muraoka H, Kawaguchi T, Kusahana E, Ono T, Kanda T, Tokuyama H, Wakino S, Itoh H. Pre-emptive short-term nicotinamide mononucleotide treatment in a mouse model of diabetic nephropathy. J Am Soc Nephrol. 2021;32(6):1355–70. https://doi.org/10.1681/ASN.2020081188.

4. Morigi M, Perico L, Benigni A. Sirtuins in renal health and disease. J Am Soc Nephrol. 2018;29(7):1799–809. https://doi.org/10.1681/ASN.2017111218.

5. Hasegawa K, Wakino S, Yoshioka K, Tatematsu S, Hara Y, Minakuchi H, Sueyasu K, Washida N, Tokuyama H, Tzukerman M, Skorecki K, Hayashi K, Itoh H. Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem. 2010;285(17):13045–56. https://doi.org/10.1074/jbc.M109.067728.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of SIRT1 in kidney diseases;International Urology and Nephrology;2024-07-19

2. Correction to: Ability of NAD and Sirt1 to epigenetically suppress albuminuria;Clinical and Experimental Nephrology;2024-06-25